Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 288

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 288
---
 follows:

| • |     | Level one - inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities; |

| • |     | Level two - inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals; and |

<div align='center'>F-4 5</div>

| • |     | Level three - unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use. |

Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. As of September 30, 2024, the Company’s milestone payment liability was measured using level three inputs. The milestone payment liability relates to contingent milestone payments for the REM-001program that was acquired in the Adgero merger (note 1).

|                             |     | September 30, 2024 |   |     |         |   |     |         |     |
|:----------------------------|:----|:-------------------|:--|:----|:--------|:--|:----|:--------|----:|
| Liability                   |     | Level 1            |   |     | Level 2 |   |     | Level 3 |     |
| Milestone payment liability |     |                    | — |     |         | — |     |         | 188 |

| Balance - June 30, 2024       |     | $(in thousands) | 186 |
|:------------------------------|:----|:----------------|----:|
| Change in fair value estimate |     |                 |   2 |
| Balance - September 30, 2024  |     |                 | 188 |

The Company’s financial instruments consist of cash and cash equivalents, other receivables, accounts payable, and related party payables. The carrying values of cash and cash equivalents, other receivables, accounts payable and related party payables approximate their fair values due to the immediate or short-term maturity of these financial instruments.

11 Subsequent events The Company has evaluated its subsequent events from September 30, 2024, through the date these condensed consolidated interim financial statements were issued and has determined that there